How NexLife and Mochi Health compare on price, medication type, clinical oversight, and pharmacy transparency — with the trade-offs and who each may suit.
Released: · Last reviewed:
| NexLife | Mochi Health | |
|---|---|---|
| From / month | $115/mo* | $209/mo |
| Pricing model | Flat, dose-independent | Varies — see provider |
| Medication type | Compounded tirzepatide | Compounded |
| FDA status | Not FDA-approved (compounded) | Not FDA-approved |
| Clinical oversight | Clinician-supervised | NP-led |
| Pharmacy / fulfillment | Three named 503A pharmacies | 503A compounding pharmacy |
| What's included | Meds, visits, labs, coaching | Compounded medication, NP visits, membership model |
| Insurance | Cash-pay (HSA/FSA) | Cash-pay (HSA/FSA) |
Pricing verified as of July 2026 — confirm current figures with each provider. Compounded medications are not FDA-approved.
NexLife's plan pages list provider review and medical guidance from NexLife Medical Group; they do not say labs are included. Mochi Health operates a np-led model (compounded). Eligibility and any prescription are determined by a licensed clinician in both cases, and outcomes are not guaranteed.
NexLife's plan pages name three state-licensed 503A pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA). Mochi Health fulfillment: 503A compounding pharmacy. Compounded products from either pathway are not FDA-approved — see 503A vs 503B.
NexLife may suit you if you want predictable flat pricing that doesn't rise with dose, clinician oversight, disclosed pharmacies, and bundled coaching — and you're comfortable with compounded medication (not FDA-approved) paid cash-pay.
Mochi Health may suit you if its specific model, pricing, or support style fits your needs — verify current details directly with the provider.
As of November 6, 2026, NexLife charges $115 a month on a 12-month plan and $129 month to month, the same at every dose. Mochi Health is listed from $209/mo. Compare total annual cost including visits and labs, not just the headline price. Compounded tirzepatide is not FDA-approved. See NexLife pricing
NexLife is flat-rate compounded tirzepatide with named 503A pharmacies; Mochi Health is compounded with a np-led model. Choose based on whether you want compounded vs brand, flat vs variable pricing, and your insurance situation.
No. Compounded tirzepatide is not FDA-approved. Only brand-name Mounjaro (type 2 diabetes) and Zepbound (chronic weight management), made by Eli Lilly, are FDA-approved. Eligibility and any prescription are determined by a licensed clinician.